Table 2.
Uni- and multivariate analyses for potential factors associated with OS of patients with bone metastases
| Variable | OS (95% CI) | Univariate analyses | Multivariate analysis | ||
|---|---|---|---|---|---|
|
|
|||||
| HR (95% CI) | p | HR (95% CI) | p | ||
| Total | 51 (38-46) | ||||
| Age | |||||
| ≤65 y | 57 (28-86) | 0.402 | |||
| >65 y | 49 (44-54) | ||||
| Tumor type | |||||
| P-NET | 48 (29-67) | 0.207 | |||
| other GEP NET | 57 (36-78) | ||||
| Performance status | |||||
| KPS ≤70 | 49 (33-65) | 0.066 | |||
| KPS >70 | 55 (35-75) | ||||
| CgA | |||||
| ≤600 ng/ml | 51 (38-64) | 0.178 | |||
| >600 ng/ml | 49 (31-67) | ||||
| NSE | |||||
| ≤15 ng/ml | 57 (48-66) | 3.9 (1.6-9.4) | 0.001 | 4.0 (1.6-9.9) | 0.002 |
| >15 ng/ml | 40 (33-47) | ||||
| Ki67 index | |||||
| ≤10% | 55 (45-65) | 2.7 (1.3-5.7) | 0.005 | 2.7 (1.3-5.7) | 0.008 |
| >10% | 30 (12-48) | ||||
| Number of lesions | |||||
| few (≤10) | 51 (42-60) | 0.451 | |||
| multiple | 43 (26-57) | ||||
OS is given as the median and in months. P-NET, pancreatic NET; KPS, Karnofsky performance score; CgA, chromogranin A; NSE, neuron-specific enolase.